Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Papa's Exit Highlights Perrigo's Shortcomings

Executive Summary

After Papa's exit from Perrigo, the company is left to pick up the pieces and is not as strong a business as investors had previously thought.

You may also be interested in...



Culture Shock In Europe For Perrigo With Branded Consumer Business

Less than a month after moving up from president to CEO, John Hendrickson tells analysts during the firm's first-quarter earnings briefing that Perrigo's private label OTC drug business remains strong, with the next launch ready to ship, but growing European branded consumer product sales is more of a long-term goal.

Stockwatch: Specialty Pharma Falling

If this downbeat first-quarter earnings season has claimed a scalp, it is the business model of specialty pharmaceutical companies. Last week the analysts from Jefferies described the specialty pharmaceutical sector as being in freefall.

Perrigo's Papa: Bridge Over Valeant's Troubled Waters Or Shark Bait?

Valeant Pharmaceuticals International Inc. hired Perrigo Co. PLC's Chairman and Chief Executive Joseph Papa to replace CEO Michael Pearson, but will Papa bridge the gaps between Valeant and its shareholders, debtors and the politicians who are demanding information about the company's drug pricing policies? Or, like Pearson, will he be bitten by the sharks in Valeant's troubled waters?

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC065174

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel